NCT03239522 - Absorption and Elimination of Radiolabeled Daprodustat | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Anaemia

Interventions

DRUG

[14C]-GSK1278863 solution for IV infusion

It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.

DRUG

[14C]-GSK1278863 oral solution

It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).

DRUG

Daprodustat 6 mg oral tablet

It is a 9.0 millimeter (mm) round, white film coated tablet.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London